In a patient with esophageal cancer who has a close relative with esophageal, gastric, or pancreatic cancer, what genetic evaluation and multigene testing should be offered, and what surveillance recommendations follow?

Genetic Evaluation for Esophageal Cancer with Family History

Patients with esophageal cancer who have a close relative with esophageal, gastric, or pancreatic cancer should be referred for genetic counseling and offered multigene panel testing that includes genes associated with hereditary diffuse gastric cancer (CDH1, CTNNA1), Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), and other hereditary cancer syndromes linked to upper GI malignancies.

When to Refer for Genetic Evaluation

Based on the most recent NCCN guidelines 1, genetic evaluation is clinically indicated when:

• ≥2 cases of gastric cancer in close relatives, with one diagnosed at age <50
• ≥3 cases of gastric cancer in close relatives
• Diffuse gastric cancer diagnosed at age <40
• Gastric cancer and 2 additional Lynch syndrome-associated cancers in the patient or close relatives

The ACMG guidelines 2 specify that referral is warranted for:

• Gastric cancer with ≥2 cases in close relatives (one diagnosed <50)
• Diffuse gastric cancer and lobular breast cancer in the same person
• Pancreatic cancer at any age if ≥2 cases of pancreatic cancer exist in close relatives

Close relatives include parents, siblings, children, aunts, uncles, nieces, nephews, grandparents, and grandchildren—all on the same side of the family 2.

Multigene Panel Testing Approach

Genes to Include

The multigene panel should encompass 3, 1, 4:

High-priority genes:

• CDH1 and CTNNA1 (hereditary diffuse gastric cancer)
• MLH1, MSH2, MSH6, PMS2, EPCAM (Lynch syndrome)
• BRCA1, BRCA2, PALB2 (hereditary breast-ovarian cancer syndrome with pancreatic/gastric cancer risk)
• STK11 (Peutz-Jeghers syndrome)
• TP53 (Li-Fraumeni syndrome)
• CDKN2A (familial atypical mole-melanoma syndrome with pancreatic cancer)
• ATM, CHEK2 (moderate penetrance genes)

Testing Methodology

• DNA sequencing plus large rearrangement analysis is required, particularly for CDH1 5
• Testing should occur early in the disease course given the limited prognosis of many esophageal cancer patients and potential therapeutic implications 3
• For CDH1 missense variants, additional functional studies are needed to assess pathogenicity 5

Surveillance Recommendations Based on Findings

If CDH1/CTNNA1 Pathogenic Variant Identified

For asymptomatic carriers 5:

Gastric surveillance:

• Annual endoscopy with minimum 30 random biopsies (Cambridge protocol) starting in late teens/early 20s if family has early-onset disease
• Prophylactic total gastrectomy is the definitive risk-reduction strategy (70% lifetime risk for men, 56% for women by age 80)
• Surveillance is appropriate for those <20 years, those declining surgery, or those with significant comorbidities

Breast surveillance (for female carriers):

• Enhanced screening given 42% lifetime risk of lobular breast cancer by age 80

If Lynch Syndrome Pathogenic Variant Identified

Based on gene-specific risks 1:

Upper GI surveillance:

• Esophagogastroduodenoscopy every 2-3 years starting at age 30-35 (or 2-5 years before earliest family diagnosis)
• Consider urothelial surveillance (urinalysis with cytology annually starting age 30-35)

Colorectal surveillance:

• Colonoscopy every 1-2 years starting age 20-25 (or 2-5 years before earliest family diagnosis)
• Annual after age 40

Endometrial/ovarian surveillance:

• Annual endometrial sampling and transvaginal ultrasound starting age 30-35
• Risk-reducing hysterectomy and bilateral salpingo-oophorectomy after childbearing

If Pancreatic Cancer-Associated Genes Identified

For BRCA1/2, PALB2, ATM, CDKN2A, STK11, or TP53 carriers 3:

Pancreatic surveillance:

• Pancreas protocol MRI/MRCP and/or endoscopic ultrasound annually starting at age 50 (or 10 years before earliest family diagnosis, but not before age 40)
• Surveillance should be performed at centers with expertise in high-risk pancreatic cancer management
• Goal is detection of high-grade dysplasia to prevent invasive cancer

Additional organ-specific surveillance:

• Gene-specific protocols for breast, ovarian, melanoma, or other associated cancers

Critical Pitfalls to Avoid

1. Don't delay testing: Germline testing should occur early in the disease course, not after treatment completion, as results may inform therapeutic decisions (e.g., platinum agents, PARP inhibitors for BRCA-related cancers) 3, 6

2. Don't test only the proband's cancer gene: Family members may harbor pathogenic variants in different genes than the proband—6.2% of relatives have unexpected actionable findings in cascade testing 7

3. Don't assume negative family history excludes hereditary risk: Up to 50% of patients with pathogenic variants don't meet traditional family history criteria 8

4. Don't use CA 19-9 for pancreatic screening: It lacks specificity and sensitivity for surveillance in high-risk individuals 3

5. Don't forget to assess for multiple syndromes: Esophageal cancer can occur in the context of tylosis, Fanconi's anemia, and other rare conditions 9

Family Member Management

Once a pathogenic variant is identified:

• All first-degree relatives should undergo single-variant testing for the familial mutation
• Consider multigene panel testing for relatives as they may harbor different actionable variants 7
• Genetic counseling should address age-appropriate testing (late teens/early 20s for high-penetrance genes with early-onset cancers)
• Discuss reproductive implications and options for preimplantation genetic diagnosis

The evidence strongly supports that this comprehensive genetic approach improves morbidity and mortality through early cancer detection, risk-reducing surgeries, and targeted therapies 3, 5, 10, 11.